Increased c-kit (CD117) expression in malignant mammary phyllodes tumors

Modern Pathology

Volumn 17, Issue 7, 2004, Pages 827-831

  Tse, Gary M K ^a   Putti, Thomas C ^b   Lui, Philip C W ^c   Lo, Anthony W I ^a   Scolyer, Richard A ^d,e   Law, Bonita K B ^a   Karim, Rooshdiya ^d,e   Lee, C Soon ^d,e  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Breast; c kit; CD117; Immunohistochemistry; Phyllodes tumor

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN BREAST PHYLLOIDES TUMOR; BENIGN TUMOR; BORDERLINE BREAST PHYLLOIDES TUMOR; BREAST TUMOR; CANCER RECURRENCE; CELL NUCLEUS; CYSTOSARCOMA PHYLLOIDES; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE C KIT; PRIORITY JOURNAL; PROTO ONCOGENE; STROMA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PHYLLODES TUMOR; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 3042533404     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800125     Document Type: Article

References (21)

1. Azzopardi JG. Sarcoma of the breast. In: Bennington J (eds). Problems in Breast Pathology, Major Problems in Pathology, Vol. II. WB Saunders: Philadelphia, 1979, pp. 355-359.
2. Palmer ML, De Risi DC, Pelikan A, et al. Treatment options and recurrence potential for cystosarcoma phyllodes. Surg Gynecol Obstet 1990;170:193-196.
3. Kario K, Meada S, Mizuno Y, et al. Phyllodes tumor of the breast: a clinicopathologic study of 34 cases. J Surg Oncol 1990;45:46-51.
4. Rowell MD, Perry RR, Hsiu JG, et al. Phyllodes tumors. Am J Surg 1993;165:376-379.
5. Cole-Beuglet C, Soriano R, Kurtz AB, et al. Ultrasound, X-ray mammography and histopathology of cystosarcoma phyllodes. Radiology 1983;146:481-486.
6. Rosen PP. Breast Pathology, 2nd edn. Lippincott-Raven: Philadelphia, 2000, pp. 176-197.
7. Ashman LK, Cambareri AC, To LB, et al. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood 1991;78:30-37.
8. Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
9. Sawyer EJ, Poulsom R, Hunt FT, et al. Malignant phyllodes tumors show stromal overexpression of c-myc and c-kit. J Pathol 2003;200:59-64.
10. Chen CM, Chen CJ, Chang CL, et al. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res 2000;94:84-91.
11. Burga AM, Tavassoli FA. Periductal stromal tumor: a rare lesion with low-grade sarcomatous behavior. Am J Surg Pathol 2003;27:343-348.
12. Tse GM, Putti TC, Kung FY, et al. Increased p53 protein expression in malignant mammary phyllodes tumors. Mod Pathol 2002;15:734-740.
13. Natali PG, Nicotra MR, Sures I, et al. Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 1992;52:713-717.
14. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994;424: 135-141.
15. Chui X, Egami H, Yamashita J, et al. Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues. Br J Cancer 1996;3:1233-1236.
16. Tsuura Y, Suzuki T, Honma K, et al. Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status. J Cancer Res Clin Oncol 2002;128:239-246.
17. Nishida K, Tsukamoto T, Uchida K, et al. Introduction of the c-kit gene leads to growth suppression of a breast cancer cell line, MCF-7. Anticancer Res 1996;16: 3397-3402.
18. Palmu S, Soderstrom KO, Quazi K, et al. Expression of C-KIT and HER-2 tyrosine kinase receptors in poorprognosis breast cancer. Anticancer Res 2002;22:411-414.
19. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec(R), Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.
20. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
21. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-1703.